Study design. *Reduced to INCB040093 100 mg twice daily (BID) and itacitinib 300 mg once daily (QD) in expansion cohorts based on safety data beyond the DLT observation period (represents RP2D for the combination). †As confirmed by immunohistochemistry.⁴⁰  GCB, germinal center B-cell-like; RP2D, recommended phase 2 dose.